| Prev Close | 326.73 |
| Open | 327.04 |
| Day Low/High | 326.26 / 336.08 |
| 52 Wk Low/High | 223.25 / 374.99 |
| Volume | 580.17K |
Biogen Inc. (BIIB)
332.56
5.80
1.80
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 149.03B |
| Market Cap | 49.06B |
| P/E Ratio | 8.89 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out
This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.
Rotation and Late-Day Strength Cover Up Mixed Action Underneath
Odd mix of moves precedes one of the most important Fed meetings in a while.
2 Small Biotech Stocks That Could See Big Gains Ahead
BioXcel Therapeutics and Albiero Pharma have promising prospects based on drugs in their pipelines.
Biogen's Japanese Partner on Alzheimer's Drug Set for Gains
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Updating Our Biogen Targets as It Soars on Alzheimer Drug Approval
Traders who went long BIIB on our April recommendation should continue to hold those shares.
Biogen Starts to Make Its Upside Move as Decision on Alzheimer's Drug Awaits
The drugmaker's charts are pointing to higher ground for its shares as a regulatory decision on its Alzheimer's drug aducanumab is at hand.
The Hour Glass Phenomena, Oh Canada, Portfolio Haircut, Earth Day, ESG Investing
Canada made the developed world's first moves toward normalizing monetary policy coming out of the pandemic, despite the fact that Canada does not seem to be flattening its own curve.
Biogen's Charts Are Ready for an Upside Breakout
Here's our first price objective.
Shock & Awe Markets, Bank Stocks, Apple's Debt Move, Trading Amazon, ServiceNow
Right off the top, the bubble has burst for the 'short squeeze' names such as GameStop and AMC Entertainment.
Real Money Post Industrial Average Feels January Chill
The RMPIA easily outpaced the main indexes for 2020, but slipped 1.7% last month.
Real Money Post Industrial Average Bests Most Major Indexes in 2020
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
Real Money Post Industrial Average Climbs 9.5% Over November
The RMPIA also tops other indexes for year, shooting ahead 29%.
Bearish Bets: 2 Biotech Stocks You Should Consider Shorting This Week
These names are displaying both technical and quantitative deterioration.
Real Money Post Industrial Average Rises 21% Year to Date
The average declined in October, but it was less than that hit took by the major indexes.
The Market Is Shrugging Off the Political News
And that is helping to create fear of missing out.
'Inside Day', Electoral Risk, Banking Stocks, Stimulus Immediately Needed
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Immatics Is a Bit Boy Who Cried Wolf
This is the type of chart that will grab the attention of momentum traders.
Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
2 Biotech Stocks to Buy on Solid Q2 Results
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
Real Money Post Industrial Average Again Outperformed, but Watch Valuations
The Real Money Post Industrial Average is up nearly 11% so far this quarter, beating all major indices, but valuations are looking stretched.
Markets at a Crossroads, Trump on Health Crisis, China to Shut Houston Consulate
The markets are really in the hands of Washington right now, and Washington is in the hands of the virus.
Real Money Post Industrial Average Outperforms, Despite Outbreak
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
I Did a Double Take When I Saw Alcoa Atop the Top 10 Trending Stocks
Let's look at the chart and see how I'd trade AA.
Biogen Jumps on Alzheimer's Drug News, But What Do the Charts Say?
Let's take a close look at BIIB and arrive at a strategy for the shares.
